GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » JiangXi Tianxin Pharmaceutical Co Ltd (SHSE:603235) » Definitions » EBIT

JiangXi Tianxin Pharmaceutical Co (SHSE:603235) EBIT : ¥589 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is JiangXi Tianxin Pharmaceutical Co EBIT?

JiangXi Tianxin Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥153 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥589 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. JiangXi Tianxin Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2024 was 19.91%. JiangXi Tianxin Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 29.55%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. JiangXi Tianxin Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 6.18%.


JiangXi Tianxin Pharmaceutical Co EBIT Historical Data

The historical data trend for JiangXi Tianxin Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JiangXi Tianxin Pharmaceutical Co EBIT Chart

JiangXi Tianxin Pharmaceutical Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 869.92 1,059.79 886.05 732.69 567.27

JiangXi Tianxin Pharmaceutical Co Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 131.12 260.24 -9.80 185.72 152.63

Competitive Comparison of JiangXi Tianxin Pharmaceutical Co's EBIT

For the Packaged Foods subindustry, JiangXi Tianxin Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JiangXi Tianxin Pharmaceutical Co's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, JiangXi Tianxin Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where JiangXi Tianxin Pharmaceutical Co's EV-to-EBIT falls into.



JiangXi Tianxin Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥589 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


JiangXi Tianxin Pharmaceutical Co  (SHSE:603235) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

JiangXi Tianxin Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=610.508 * ( 1 - 16.04% )/( (2496.802 + 2651.472)/ 2 )
=512.5825168/2574.137
=19.91 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5090.159 - 285.526 - ( 2307.831 - max(0, 461.328 - 3121.312+2307.831))
=2496.802

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5249.611 - 218.326 - ( 2379.813 - max(0, 508.888 - 3236.584+2379.813))
=2651.472

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

JiangXi Tianxin Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=610.508/( ( (1618.344 + max(397.062, 0)) + (1634.805 + max(482.366, 0)) )/ 2 )
=610.508/( ( 2015.406 + 2117.171 )/ 2 )
=610.508/2066.2885
=29.55 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(227.759 + 478.965 + 48.47) - (285.526 + 0 + 72.606)
=397.062

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(265.009 + 434.43 + 68.824) - (218.326 + 0 + 67.571)
=482.366

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

JiangXi Tianxin Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=588.775/9532.009
=6.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


JiangXi Tianxin Pharmaceutical Co EBIT Related Terms

Thank you for viewing the detailed overview of JiangXi Tianxin Pharmaceutical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


JiangXi Tianxin Pharmaceutical Co (SHSE:603235) Business Description

Traded in Other Exchanges
N/A
Address
Le'anjiang Industrial Park, Jiangxi Province, Leping, CHN, 333300
JiangXi Tianxin Pharmaceutical Co Ltd is engaged in the research and development, production and sales of monomeric vitamin products.

JiangXi Tianxin Pharmaceutical Co (SHSE:603235) Headlines

No Headlines